SCM
NTLA icon

Steadfast Capital Management’s Intellia Therapeutics NTLA Stock Holding History

Steadfast Capital Management’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-365,400
Closed -$6.31M – 156
2025
Q3 		$6.31M Buy
+365,400
New +$4.5M 0.11% 79

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Steadfast Capital Management's NTLA Position: Q4 2025 in Review

Steadfast Capital Management sold out of Intellia Therapeutics (NTLA) in Q4 2025, closing a stake of 365,400 shares — an estimated $6.31M sold.

Steadfast Capital Management first reported a position in NTLA in Q3 2025 and held it in 1 quarter. The position peaked at $6.31M in Q3 2025. 291 funds tracked by Wall St. Rank hold NTLA as of Q4 2025.

  • Steadfast Capital Management reported no remaining Intellia Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Steadfast Capital Management sold 365,400 Intellia Therapeutics shares in Q4 2025, an estimated $6.31M.
  • Steadfast Capital Management first reported a position in Intellia Therapeutics in Q3 2025 and held it in 1 quarter.
  • Steadfast Capital Management's Intellia Therapeutics position peaked at $6.31M in Q3 2025.
  • 291 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2025.

Based on Steadfast Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.